Streetbeat News

Regulatory

CYCC

CYCCP

Cyclacel Pharmaceuticals, Inc. has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Form 10-Q for Q3 2023. The Nasdaq Listing Qualifications Department confirmed Cyclacel's compliance and closed the matter.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:19 pm

BCRX

BioCryst Pharmaceuticals, according to an SEC filing, will receive a 20% royalty on annual Japanese sales below a certain threshold and an 80% royalty on sales above that threshold.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:16 pm

BXRX

BioCryst Pharmaceuticals has revised its agreement with Torii Pharmaceutical regarding ORLADEYO in Japan. BioCryst Japan K.K. will now handle all commercial promotion, while Torii focuses on hereditary angioedema disease awareness activities, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:11 pm

AAPL

AMKR

Amkor Technology, Inc. (NASDAQ:AMKR) plans to build a $2 billion advanced packaging and test facility in Peoria, Arizona, creating approximately 2,000 jobs. The facility, which will be the largest outsourced advanced packaging facility in the US, is supported by the CHIPS and Science Act and has Apple (NASDAQ:AAPL) as its first and largest customer. The project is part of efforts to strengthen the US semiconductor supply chain and reduce dependence on foreign manufacturing.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:10 pm

MMAT

Meta Materials has submitted a request for a hearing to appeal the NASDAQ Staff's delisting determination. The company's common stock will continue to trade on the NASDAQ Capital Market under the symbol 'MMAT' while the hearing process is ongoing, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:37 pm

MMAT

Meta Materials received a letter from Nasdaq on November 27, informing the company that Nasdaq has decided to delist its common stock from the Nasdaq Capital Market, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:36 pm

EWTX

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA for EDG-5506, a treatment for Duchenne and Becker muscular dystrophy. EDG-5506 is an investigational drug currently in Phase 2 trials. ODD and RPDD provide benefits such as market exclusivity, tax credits, and fee waivers, which support the development of rare disease treatments.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:11 pm

WLDS

Wearable Devices Ltd. has filed a U.S. patent for a touchless pinch-to-zoom interaction technology for augmented reality (AR) wearables. This technology allows users to adjust parameters using hand and wrist gestures without physical contact.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:11 pm

BIAF

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW) announced CMS' final payment determination for CyPath Lung, a noninvasive lung cancer test, effective January 2024. This facilitates reimbursement by Medicare and private payers, aiding commercialization. The AMA issued CPT code 0406U for CyPath Lung in June 2023, with CMS finalizing payment in November 2023. CyPath Lung uses flow cytometry and AI for early-stage lung cancer detection, showing high sensitivity and specificity in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:11 pm

AZN

Presage Biosciences has partnered with AstraZeneca to use its CIVO technology for evaluating novel immuno-oncology drug combinations in head and neck cancer patients. This collaboration aims to advance AstraZeneca's portfolio of immuno-oncology agents. Earlier, Presage presented a study at SITC 2023 showing the effectiveness of CIVO in analyzing Merck's KEYTRUDA in patient tumors, highlighting the limitations of animal studies compared to the intact tumor microenvironment.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:05 pm